Insight Molecular Diagnostics Inc. (IMDX)
NASDAQ: IMDX · Real-Time Price · USD
4.940
-0.050 (-1.00%)
Jul 23, 2026, 11:56 AM EDT - Market open
IMDX Revenue
Insight Molecular Diagnostics had revenue of $32.00K in the quarter ending March 31, 2026, a decrease of -98.50%. This brings the company's revenue in the last twelve months to $1.95M, down -49.28% year-over-year. In the year 2025, Insight Molecular Diagnostics had annual revenue of $4.06M with 115.58% growth.
Revenue (ttm)
$1.95M
Revenue Growth
-49.28%
P/S Ratio
82.67
Revenue / Employee
$33,603
Employees
58
Market Cap
159.51M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.06M | 2.17M | 115.58% |
| Dec 31, 2024 | 1.88M | 378.00K | 25.15% |
| Dec 31, 2023 | 1.50M | 545.00K | 56.89% |
| Dec 31, 2022 | 958.00K | -1.24M | -56.41% |
| Dec 31, 2021 | 2.20M | 982.00K | 80.76% |
| Dec 31, 2020 | 1.22M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Myriad Genetics | 829.00M |
| OPKO Health | 581.12M |
| Castle Biosciences | 339.92M |
| Fulgent Genetics | 320.35M |
| MDxHealth | 110.97M |
| Biodesix | 96.10M |
| Burning Rock Biotech | 74.58M |
| Exagen | 68.38M |
IMDX News
- 2 hours ago - Insight Molecular Diagnostics highlights Lancet study on GraftAssure assay - TheFly
- 4 hours ago - iMDx GraftAssure Assay Guides Use of Potentially Kidney-Graft-Saving Drug in New Lancet Group Publication - GlobeNewsWire
- 6 days ago - Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio - GlobeNewsWire
- 24 days ago - IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper - GlobeNewsWire
- 4 weeks ago - iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant - GlobeNewsWire
- 5 weeks ago - Favorable Head-to-Head Data on iMDx's GraftAssure with Competing NGS Assay Published in Clinical Chemistry - GlobeNewsWire
- 5 weeks ago - IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation - GlobeNewsWire
- 6 weeks ago - iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress - GlobeNewsWire